SB-200646 (CAT: I015594) is the first selective antagonist of the 5-HT2B and 5-HT2C receptors, with a higher affinity for these receptor subtypes compared to the 5-HT2A receptor. This selectivity allows SB-200646 to selectively block the actions of serotonin (5-HT) on the 5-HT2B and 5-HT2C receptors while sparing the 5-HT2A receptor. By antagonizing the 5-HT2B and 5-HT2C receptors, SB-200646 can modulate the effects of serotonin in various physiological processes and potentially provide therapeutic benefits.
| Catalog Number | I015594 |
| CAS Number | 143797-63-1 |
| Molecular Formula | C₁₅H₁₄N₄O |
| Purity | 95% |
| Reference | [1]. Blackburn TP, et al. The acute and chronic administration of the 5-HT(2B/2C) receptor antagonist SB-200646A significantly alters the activity of spontaneously active midbrain dopamine neurons in the rat: An in vivo extracellular single cell study. Synapse. 2006 Jun 15;59(8):502-12.<br>[2]. Kennett GA, et al. In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist. Br J Pharmacol. 1994 Mar;111(3):797-802.<br>[3]. Theile JW, et al. Role of 5-hydroxytryptamine2C receptors in Ca2+-dependent ethanol potentiation of GABA release onto ventral tegmental area dopamine neurons. J Pharmacol Exp Ther. 2009 May;329(2):625-33. |
